BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25991065)

  • 41. Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization.
    Agiba AM; Abdel-Hamid S; Nasr M; Geneidi AS
    Curr Drug Deliv; 2018 Feb; 15(2):267-277. PubMed ID: 28322163
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heat induced evaporative antisolvent nanoprecipitation (HIEAN) of itraconazole.
    Mugheirbi NA; Paluch KJ; Tajber L
    Int J Pharm; 2014 Aug; 471(1-2):400-11. PubMed ID: 24879938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of isradipine loaded self-nano emulsifying powders for improved oral delivery: in vitro and in vivo evaluation.
    Ramasahayam B; Eedara BB; Kandadi P; Jukanti R; Bandari S
    Drug Dev Ind Pharm; 2015 May; 41(5):753-63. PubMed ID: 24641324
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tablet formulation of Famotidine-loaded P-gp inhibiting nanoparticles using PLA-g-PEG grafted polymer.
    Mokhtar M; Gosselin PM; François-Xavier L; Hildgen P
    Pharm Dev Technol; 2019 Feb; 24(2):211-221. PubMed ID: 29564944
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport.
    Mellaerts R; Mols R; Kayaert P; Annaert P; Van Humbeeck J; Van den Mooter G; Martens JA; Augustijns P
    Int J Pharm; 2008 Jun; 357(1-2):169-79. PubMed ID: 18325700
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formulation and evaluation of Cetirizine dihydrochloride orodispersible tablet.
    Subramanian S; Sankar V; Manakadan AA; Ismail S; Andhuvan G
    Pak J Pharm Sci; 2010 Apr; 23(2):232-5. PubMed ID: 20363705
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tracking of crystalline-amorphous transition of carvedilol in rotary spun microfibers and their formulation to orodispersible tablets for in vitro dissolution enhancement.
    Szabó P; Sebe I; Stiedl B; Kállai-Szabó B; Zelkó R
    J Pharm Biomed Anal; 2015 Nov; 115():359-67. PubMed ID: 26280924
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preparation, characterization and tableting of cilnidipine solid dispersions.
    Hu L; Song W; Niu F; Jiao K; Jia Z
    Pak J Pharm Sci; 2013 May; 26(3):629-36. PubMed ID: 23625441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Application of β-cyclodextrin in the formulation of ODT tablets containing ibuprofen].
    Zimmer Ł; Kasperek R; Poleszak E
    Polim Med; 2014; 44(4):231-5. PubMed ID: 25932904
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
    Mou D; Chen H; Wan J; Xu H; Yang X
    Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physicochemical, Pharmacodynamic and Pharmacokinetic Characterization of Soluplus Stabilized Nanosuspension of Tacrolimus.
    Varshosaz J; Minayian M; Yazdekhasti S
    Curr Drug Deliv; 2017; 14(4):521-535. PubMed ID: 27697037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Formulation, development, and performance evaluation of metoclopramide HCl oro-dispersible sustained release tablet.
    Kasliwal N; Negi JS; Jugran V; Jain R
    Arch Pharm Res; 2011 Oct; 34(10):1691-700. PubMed ID: 22076769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole.
    Kumar S; Jog R; Shen J; Zolnik B; Sadrieh N; Burgess DJ
    J Pharm Sci; 2015 Sep; 104(9):3018-28. PubMed ID: 25195539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Formulation and characterization study of itraconazole-loaded microparticles.
    Segale L; Giovannelli L; Mannina P; Pattarino F
    Pharm Dev Technol; 2015 Mar; 20(2):153-8. PubMed ID: 24219826
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nanocrystal-based per-oral itraconazole delivery: superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption.
    Sarnes A; Kovalainen M; Häkkinen MR; Laaksonen T; Laru J; Kiesvaara J; Ilkka J; Oksala O; Rönkkö S; Järvinen K; Hirvonen J; Peltonen L
    J Control Release; 2014 Apr; 180():109-16. PubMed ID: 24566254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations.
    Rasool BK; Fahmy SA; Galeel OW
    Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improved bioavailability of aceclofenac from spherical agglomerates: development, in vitro and preclinical studies.
    Muatlik S; Usha AN; Reddy MS; Ranjith AK; Pandey S
    Pak J Pharm Sci; 2007 Jul; 20(3):218-26. PubMed ID: 17545107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preparation and evaluation of itraconazole dihydrochloride for the solubility and dissolution rate enhancement.
    Tao T; Zhao Y; Wu J; Zhou B
    Int J Pharm; 2009 Feb; 367(1-2):109-14. PubMed ID: 18930795
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preparation of rapidly disintegrating tablets containing itraconazole solid dispersions.
    Oshima T; Sonoda R; Ohkuma M; Sunada H
    Chem Pharm Bull (Tokyo); 2007 Nov; 55(11):1557-62. PubMed ID: 17978511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Enhancement of docetaxel solubility using binary and ternary solid dispersion systems.
    Lim SM; Pang ZW; Tan HY; Shaikh M; Adinarayana G; Garg S
    Drug Dev Ind Pharm; 2015; 41(11):1847-55. PubMed ID: 25721984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.